Alcoholic Liver Disease

Zakim and Boyer's Hepatology

Volumn , Issue , 2006, Pages 579-623

  Stewart, Stephen F ^a   Day, Christopher P ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882832916     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-3258-8.50034-6     Document Type: Chapter

References (446)

1. Lelbach WK Epidemiology of alcoholic liver disease: continental Europe. Alcoholic liver disease 1985, 130-166. Edward Arnold, London. P. Hall (Ed.).
2. Masse L, Juillan JM, Chisloup A Trends in mortality from cirrhosis of the liver, 1950-1971. World health statistics report. Rapport de Statistiques Sanitaires Mondiales 1976, 29:40-67.
3. Mandayam S, Jamal MM, Morgan TR Epidemiology of alcoholic liver disease. Semin Liver Dis 2004, 24:217-232.
4. Naveau S, Giraud V, Borotto E, et al. Excess weight risk factor for alcoholic liver disease. Hepatology 1997, 25(1):108-111.
5. Yoon Y-H, Yi HY, Smothers BA Liver cirrhosis mortality in the United States 1970-2001; surveillance report #67, NIAAA: 2004 Available online at . http://www.niaaa.gov.
6. Rubin E, Lieber CS Experimental alcoholic hepatitis: a new primate model. Science 1973, 182:712-713.
7. Anley CC, Senapati A, Brown IM, et al. Is alcohol hepatotoxic in the baboon?. J Hepatol 1988, 7:85-92.
8. Berggren S, Goldberg L. The absorption of ethyl alcohol from the gastrointestinal tract as a diffusion process. Acta Physiol Scand 1940, 1:246-270.
9. Marshall AW, Kingstone D, Boss M, Morgan MY Ethanol elimination in males and females: relationship to menstrual cycle and body composition. Hepatology 1983, 3:701-706.
10. Caballeria J, Baraona E, Lieber CS The contribution of the stomach to ethanol oxidation in the rat. Life Sci 1987, 41:1021-1027.
11. Frezza M, di Padova C, Pozzato G, et al. High blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism [comment] [erratum appears in. N Engl J Med 1990, 323:553.
12. N Engl J Med 1990, 322:95-99.
13. Parlesak A, Billinger MH, Bode C, Bode JC Gastric alcohol dehydrogenase activity in man: influence of gender, age, alcohol consumption and smoking in a caucasian population. Alcohol Alcoholism 2002, 37:388-393.
14. Caballeria J, Baraona E, Rodamilans B, Lieber CS Effects of cimetidine on gastric alcohol dehydrogenase activity and blood ethanol levels [comment]. Gastroenterology 1989, 96:388-392.
15. Brown AS, Fiaterone JR, Day CP, et al. Ranitidine increases the bioavailability of postprandial ethanol by the reduction of first pass metabolism. Gut 1995, 37:413-417.
16. Brown AS, Fiaterone JR, Wood P, et al. The effect of gastritis on human gastric alcohol dehydrogenase activity and ethanol metabolism. Aliment Pharmacol Ther 1995, 9:57-61.
17. Vallee BL, Bazzone TJ Isozymes of human liver alcohol dehydrogenase. Isozymes: Curr Topics Biol Med Res 1983, 8:219-244.
18. Bosron WF, Li TK Genetic polymorphism of human liver alcohol and aldehyde dehydrogenases, and their relationship to alcohol metabolism and alcoholism. Hepatology 1986, 6:502-510.
19. Moreno A, Pares X. Purification and characterization of a new alcohol dehydrogenase from human stomach. J Biol Chem 1991, 266:1128-1133.
20. Lester D, Keokosky WZ Alcohol metabolism in the horse. Life Sci 1967, 6:2313-2319.
21. Lieber CS, DeCarli LM Ethanol oxidation by hepatic microsomes: adaptive increase after ethanol feeding. Science 1968, 162:917-918.
22. Umeno M, McBride OW, Yang CS, et al. Human ethanol-inducible P450IIE1: complete gene sequence, promoter characterization, chromosome mapping, and cDNA-directed expression. Biochemistry 1988, 27:9006-9013.
23. Seeff LB, Cuccherini BA, Zimmerman HJ, et al. Acetaminophen hepatotoxicity in alcoholics. A therapeutic misadventure. Ann Intern Med 1986, 104:399-404.
24. Zimmerman HJ, Maddrey WC Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. Hepatology 1995, 22:767-773.
25. Nagai H, Matsumaru K, Feng G, Kaplowitz N. Reduced glutathione depletion causes necrosis and sensitization to tumor necrosis factor-alpha-induced apoptosis in cultured mouse hepatocytes. Hepatology 2002, 36:55-64.
26. Gordon GG, Altman K, Southren AL, et al. Effect of alcohol (ethanol) administration on sex-hormone metabolism in normal men. N Engl J Med 1976, 295:793-797.
27. Boveris A, Oshino N, Chance B. The cellular production of hydrogen peroxide. Biochem J 1972, 128:617-630.
28. Smith M. Genetics of human alcohol and aldehyde dehydrogenases. Adv Hum Genet 1986, 15:249-290.
29. Goedde HW, Agarwal DP Polymorphism of aldehyde dehydrogenase and alcohol sensitivity. Enzyme 1987, 37:29-44.
30. Crabb DW, Edenberg HJ, Bosron WF, Li TK Genotypes for aldehyde dehydrogenase deficiency and alcohol sensitivity. The inactive ALDH2 (2) allele is dominant. J Clin Invest 1989, 83:314-316.
31. Enomoto N, Takase S, Takada N, Takada A. Alcoholic liver disease in heterozygotes of mutant and normal aldehyde dehydrogenase-2 genes. Hepatology 1991, 13:1071-1075.
32. Bernstein J, Videla L, Israel Y. Hormonal influences in the development of the hypermetabolic state of the liver produced by chronic administration of ethanol. J Pharmacol Exp Ther 1975, 192(3):583-591.
33. Lieberman FL The effect of liver diseases on the rate of ethanol metabolism in man. Gastroenterology 1963, 44:261-266.
34. Figueroa RB, Klatz AP Alterations of liver alcohol dehydrogenase and other hepatic enzymes in alcoholic cirrhosis. Gastroenterology 1962, 43(10).
35. Korsten MA, Matsuzaki S, Feinman L, Lieber CS High blood acetaldehyde levels after ethanol administration. Difference between alcoholic and nonalcoholic subjects. N Engl J Med 1975, 292:386-389.
36. Lindros KO, Stowell A, Pikkarainen P, Salaspuro M Elevated blood acetaldehyde in alcoholics with accelerated ethanol elimination. Pharmacol Biochem Behav 1980, 13(suppl 1):119-124.
37. Nuutinen H, Lindros KO, Salaspuro M Determinants of blood acetaldehyde level during ethanol oxidation in chronic alcoholics. Alcoholism Clin Exp Res 1983, 7:163-168.
38. Day CP, Yeaman SJ Physical evidence for the presence of two forms of phosphatidate phosphohydrolase in rat liver. Biochim Biophys Acta 1992, 1127:87-94.
39. Nanji AA, Tsukamoto H, French SW Relationship between fatty liver and subsequent development of necrosis, inflammation and fibrosis in experimental alcoholic liver disease. Exp Mol Pathol 1989, 51:141-148.
40. Elabbadi N, Day CP, Gamouth A, et al. Relationship between the inhibition of phosphatidic acid phosphohydrolase-1 by oleate and oleoyl-CoA ester and its apparent translocation. Biochimie 2005, 87:437-443.
41. Aoyama T, Peters JM, Iritani N, et al. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha). J Biol Chem 1998, 273:5678-5684.
42. Galli A, Pinaire J, Fischer M, et al. The transcriptional and DNA binding activity of peroxisome proliferator-activated receptor alpha is inhibited by ethanol metabolism. A novel mechanism for the development of ethanol-induced fatty liver. J Biol Chem 2001, 276:68-75.
43. Fischer M, You M, Matsumoto M, Crabb DW Peroxisome proliferator-activated receptor alpha (PPARalpha) agonist treatment reverses PPARalpha dysfunction and abnormalities in hepatic lipid metabolism in ethanol-fed mice. J Biol Chem 2003, 278:27997-28004.
44. Nanji AA, Dannenberg AJ, Jokelainen K, Bass NM Alcoholic liver injury in the rat is associated with reduced expression of peroxisome proliferator-alpha (PPARalpha)-regulated genes and is ameliorated by PPARalpha activation. J Pharmacol Exp Ther 2004, 310:417-424.
45. Nakajima T, Kamijo Y, Tanaka N, et al. Peroxisome proliferator-activated receptor alpha protects against alcohol-induced liver damage [see comment]. Hepatology 2004, 40:972-980.
46. Tuma DJ, Smith SL, Sorrell MF Acetaldehyde and microtubules. Ann NY Acad Sci 1991, 625:786-792.
47. Yoon Y, Torok N, Krueger E, et al. Ethanol-induced alterations of the microtubule cytoskeleton in hepatocytes. Am J Physiol 1998, 274:G757-G766.
48. Sugimoto T, Yamashita S, Ishigami M, et al. Decreased microsomal triglyceride transfer protein activity contributes to initiation of alcoholic liver steatosis in rats. J Hepatol 2002, 36:157-162.
49. Yin M, Wheeler MD, Kono H, et al. Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice. Gastroenterology 1999, 117:942-952.
50. Ueki K, Kondo T, Tseng YH, Kahn CR Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc Natl Acad Sci USA 2004, 101:10422-10427.
51. Xu A, Wang Y, Keshaw H, et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003, 112:91-100.
52. Villanueva JA, Halsted CH Hepatic transmethylation reactions in micropigs with alcoholic liver disease. Hepatology 2004, 39:1303-1310.
53. Kenyon SH, Nicolaou A, Gibbons WA The effect of ethanol and its metabolites upon methionine synthase activity in vitro. Alcohol 1998, 15:305-309.
54. Mori K. Tripartite management of unfolded proteins in the endoplasmic reticulum. Cell 2000, 101:451-454.
55. Kaufman RJ Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls. Genes Dev 1999, 13:1211-1233.
56. Outinen PA, Sood SK, Pfeifer SI, et al. Homocysteine-induced endoplasmic reticulum stress and growth arrest leads to specific changes in gene expression in human vascular endothelial cells. Blood 1999, 94:959-967.
57. You M, Fischer M, Deeg MA, Crabb DW Ethanol induces fatty acid synthesis pathways by activation of sterol regulatory element-binding protein (SREBP). J Biol Chem 2002, 277:29342-29347.
58. You M, Matsumoto M, Pacold CM, et al. The role of AMP-activated protein kinase in the action of ethanol in the liver. Gastroenterology 2004, 127:1798-1808.
59. Ji C, Kaplowitz N. Betaine decreases hyperhomocysteinemia, endoplasmic reticulum stress, and liver injury in alcohol-fed mice. Gastroenterology 2003, 124:1488-1499.
60. Ji C, Deng Q, Kaplowitz N. Role of TNF-alpha in ethanol-induced hyperhomocysteinemia and murine alcoholic liver injury. Hepatology 2004, 40:442-451.
61. Day CP, James OF Hepatic steatosis: innocent bystander or guilty party?. Hepatology 1998, 27:1463-1466.
62. Sorensen TI, Orholm M, Bentsen KD, et al. Prospective evaluation of alcohol abuse and alcoholic liver injury in men as predictors of development of cirrhosis. Lancet 1984, 2:241-244.
63. Teli MR, Day CP, Burt AD, et al. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver [comment]. Lancet 1995, 346:987-990.
64. Yang SQ, Lin HZ, Lane MD, et al. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci USA 1997, 94:2557-2562.
65. Letteron P, Fromenty B, Terris B, et al. Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice. J Hepatol 1996, 24:200-208.
66. Guebre-Xabier M, Yang S, Lin R, et al. Altered hepatic lymphocyte subpopulations in obesity-related murine fatty livers: potential mechanism for sensitization to liver damage. Hepatology 2000, 31:633-640.
67. Halliwell B. Free radicals, antioxidants, and human disease: curiosity, cause, or consequence?. [see comments] Lancet 1994, 344:721-724.
68. Parola M, Robino G. Oxidative stress-related molecules and liver fibrosis. J Hepatol 2001, 35:297-306.
69. Clot P, Tabone M, Arico S, Albano E. Monitoring oxidative damage in patients with liver cirrhosis and different daily alcohol intake. Gut 1994, 35:1637-1643.
70. Paradis V, Kollinger M, Fabre M, et al. In situ detection of lipid peroxidation by-products in chronic liver diseases. Hepatology 1997, 26:135-142.
71. Situnayake RD, Crump BJ, Thurnham DI, et al. Lipid peroxidation and hepatic antioxidants in alcoholic liver disease. Gut 1990, 31:1311-1317.
72. Ekstrom G, Ingelman-Sundberg M Rat liver microsomal NADPH-supported oxidase activity and lipid peroxidation dependent on ethanol-inducible cytochrome P-450 (P-450IIE1). Biochem Pharmacol 1989, 38:1313-1319.
73. Albano E, Tomasi A, Goria-Gatti L, Dianzini MU Spin trapping of free radical species produced during the microsomal metabolism of ethanol. Chem-Biol Interact 1988, 65:223-234.
74. Slater TF, Sawyer BC, Strauli UD Changes in liver nucleotide concentrations in experimental liver injury. 2. Acute ethanol poisoning. Biochem J 1964, 93:267-270.
75. Albano E, Clot P, Morimoto M, et al. Role of cytochrome P4502E1-dependent formation of hydroxyethyl free radical in the development of liver damage in rats intragastrically fed with ethanol. Hepatology 1996, 23:155-163.
76. Morimoto M, Hagbjork AL, Nanji AA, et al. Role of cytochrome P4502E1 in alcoholic liver disease pathogenesis. Alcohol 1993, 10:459-464.
77. Kukielka E, Dicker E, Cederbaum AI Increased production of reactive oxygen species by rat liver mitochondria after chronic ethanol treatment. Arch Biochem Biophys 1994, 309:377-386.
78. Ma MH Ultrastructural pathologic findings of the human hepatocyte. I. Alcoholic liver disease. Arch Pathol 1972, 94:554-571.
79. Arai M, Leo MA, Nakano M, et al. Biochemical and morphological alterations of baboon hepatic mitochondria after chronic ethanol consumption. Hepatology 1984, 4:165-174.
80. Brown GC Nitric oxide regulates mitochondrial respiration and cell functions by inhibiting cytochrome oxidase. FEBS Lett 1995, 369:136-139.
81. Poderoso JJ, Carreras MC, Lisdero C, et al. Nitric oxide inhibits electron transfer and increases superoxide radical production in rat heart mitochondria and submitochondrial particles. Arch Biochem Biophys 1996, 328:85-92.
82. McKim SE, Gabele E, Isayama F, et al. Inducible nitric oxide synthase is required in alcohol-induced liver injury: studies with knockout mice. Gastroenterology 2003, 125:1834-1844.
83. Niemela O, Parkkila S, Bradford B, et al. Effect of Kupffer cell inactivation on ethanol-induced protein adducts in the liver. Free Radical Biol Med 2002, 33:350-355.
84. Kono H, Rusyn I, Yin M, et al. NADPH oxidase-derived free radicals are key oxidants in alcohol-induced liver disease. J Clin Invest 2000, 106:867-872.
85. Paredes SR, Kozicki PA, Fukuda H, et al. S-adenosyl-L-methionine: its effect on aminolevulinate dehydratase and glutathione in acute ethanol intoxication. Alcohol 1987, 4:81-85.
86. Hirano T, Kaplowitz H, Tsukamoto H, et al. Hepatic mitochondrial glutathione depletion and progression of experimental alcoholic liver disease in rats. Hepatology 1992, 16:1423-1427.
87. Colell A, Garcia-Ruiz C, Miranda M, et al. Selective glutathione depletion of mitochondria by ethanol sensitizes hepatocytes to tumor necrosis factor. Gastroenterology 1998, 115:1541-1551.
88. Song Z, Zhou Z, Uriarte S, et al. S-adenosylhomocysteine sensitizes to TNF-alpha hepatotoxicity in mice and liver cells: a possible etiological factor in alcoholic liver disease. Hepatology 2004, 40:989-997.
89. Dworkin B, Rosenthal WS, Jankowski RH, et al. Low blood selenium levels in alcoholics with and without advanced liver disease. Correlations with clinical and nutritional status. Digest Dis Sci 1985, 30:838-844.
90. Thurnham DI, Davies JA, Crump BJ, et al. The use of different lipids to express serum tocopherol: lipid ratios for the measurement of vitamin E status. Ann Clin Biochem 1986, 23:514-520.
91. Leo MA, Lieber CS Hepatic vitamin A depletion in alcoholic liver injury. N Engl J Med 1982, 307:597-601.
92. Bianchi GP, Fiorella PL, Bargossi AM, et al. Reduced ubiquinone plasma levels in patients with liver cirrhosis and in chronic alcoholics. Liver 1994, 14:138-140.
93. Stewart SF, Prince M, Bassendine MF, et al. A trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. J Hepatol 2002, 36(suppl 1):16.
94. Nanji AA, Mendenhall CL, French SW Beef fat prevents alcoholic liver disease in the rat. Alcohol Clin Exp Res 1989, 13:15-19.
95. Nanji AA, French SW Dietary linoleic acid is required for development of experimentally induced alcoholic liver injury. Life Sci 1989, 44:223-227.
96. Nanji AA, Zhao S, Sadrzadeh SM, et al. Markedly enhanced cytochrome P450 2E1 induction and lipid peroxidation is associated with severe liver injury in fish oil-ethanol-fed rats. Alcohol Clin Exp Res 1994, 18:1280-1285.
97. Arias-Negrete S, Keller K, Chadee K. Proinflammatory cytokines regulate cyclooxygenase-2 mRNA expression in human macrophages. Biochem Biophys Res Commun 1995, 208:582-589.
98. Tsukamoto H, Horne W, Kamimura S, et al. Experimental liver cirrhosis induced by alcohol and iron. J Clin Invest 1995, 96:620-630.
99. Kessova IG, Ho YS, Thung S, Cederbaum AI Alcohol-induced liver injury in mice lacking Cu, Zn-superoxide dismutase. Hepatology 2003, 38:1136-1145.
100. Lu SC, Alvarez L, Huang ZZ, et al. Methionine adenosyltransferase 1A knockout mice are predisposed to liver injury and exhibit increased expression of genes involved in proliferation. Proc Natl Acad Sci USA 2001, 98:5560-5565.
101. Lieber CS S-Adenosyl-L-methionine and alcoholic liver disease in animal models: implications for early intervention in human beings. Alcohol 2002, 27:173-177.
102. Sadrzadeh SM, Nanji AA, Price PL The oral iron chelator, 1,2-dimethyl-3-hydroxypyrid-4-one reduces hepatic-free iron, lipid peroxidation and fat accumulation in chronically ethanol-fed rats. J Pharmacol Exp Ther 1994, 269:632-636.
103. Wheeler MD, Nakagami M, Bradford BU, et al. Overexpression of manganese superoxide dismutase prevents alcohol-induced liver injury in the rat. J Biol Chem 2001, 276:36664-36672.
104. 14C]acetaldehyde to serum albumin. Arch Biochem Biophys 1983, 220:239-246.
105. Tuma DJ, Jennett RB, Sorrell MF The interaction of acetaldehyde with tubulin. Ann NY Acad Sci 1987, 492:277-286.
106. Stevens VJ, Fantl WJ, Newman CB, et al. Acetaldehyde adducts with hemoglobin. J Clin Invest 1981, 67(2):361-369.
107. Tuma DJ, Sorrell MF Covalent binding of acetaldehyde to hepatic proteins: role in alcoholic liver injury. Progr Clin Biol Res 1985, 183:3-17.
108. Behrens UJ, Ma XL, Bychenok S, et al. Acetaldehyde-collagen adducts in CCl4-induced liver injury in rats. Biochem Biophys Res Commun 1990, 173:111-119.
109. Behrens UJ, Hoerner M, Lasker JM, Lieber CS Formation of acetaldehyde adducts with ethanol-inducible P450IIE1 in vivo. Biochem Biophys Res Commun 1988, 154:584-590.
110. Mauch TJ, Donohue TM, Zetterman RK, et al. Covalent binding of acetaldehyde selectively inhibits the catalytic activity of lysine-dependent enzymes. Hepatology 1986, 6:263-269.
111. Matsuda Y, Baraona E, Salaspuro M, Lieber CS Effects of ethanol on liver microtubules and Golgi apparatus. Possible role in altered hepatic secretion of plasma proteins. Lab Invest 1979, 41:455-463.
112. Baraona E, Pikkarainen P, Salaspuro M, Lieber CS Acute effects of ethanol on hepatic protein synthesis and secretion in the rat. Gastroenterology 1980, 79:104-111.
113. Zhu Y, Fillenwarth MJ, Crabb D, et al. Identification of the 37-kd rat liver protein that forms an acetaldehyde adduct in vivo as delta 4-3-ketosteroid 5 beta-reductase. Hepatology 1996, 23:115-122.
114. Pastorino JG, Hoek JB Ethanol potentiates tumor necrosis factor-alpha cytotoxicity in hepatoma cells and primary rat hepatocytes by promoting induction of the mitochondrial permeability transition. Hepatology 2000, 31:1141-1152.
115. Lluis JM, Colell A, Garcia-Ruiz C, et al. Acetaldehyde impairs mitochondrial glutathione transport in HepG2 cells through endoplasmic reticulum stress. Gastroenterology 2003, 124:708-724.
116. Nolan JP Intestinal endotoxins as mediators of hepatic injury - an idea whose time has come again. Hepatology 1989, 10:887-891.
117. Fukui H, Brauner B, Bode JC, Bode C Plasma endotoxin concentrations in patients with alcoholic and non-alcoholic liver disease: reevaluation with an improved chromogenic assay. J Hepatol 1991, 12:162-169.
118. 2. Am J Pathol 1993, 142:367-373.
119. Schumann RR, Leong SR, Flaggs GW, et al. Structure and function of lipopolysaccharide-binding protein. Science 1990, 249:1429-1431.
120. Wright SD, Ramos RA, Tobias PS, et al. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990, 249:1431-1433.
121. Poltorak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998, 282:2085-2088.
122. Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells [comment]. Science 2003, 299:1033-1036.
123. Tsukamoto H, Reidelberger RD, French SW, Largman C. Long-term cannulation model for blood sampling and intragastric infusion in the rat. Am J Physiol 1984, 247:R595-R599.
124. Adachi Y, Moore LE, Bradford BU, et al. Antibiotics prevent liver injury in rats following long-term exposure to ethanol. Gastroenterology 1995, 108:218-224.
125. Uesugi T, Froh M, Arteel GE, et al. Toll-like receptor 4 is involved in the mechanism of early alcohol-induced liver injury in mice. Hepatology 2001, 34:101-108.
126. Jarvelainen HA, Orpana A, Perola M, et al. Promoter polymorphism of the CD14 endotoxin receptor gene as a risk factor for alcoholic liver disease [see comment]. Hepatology 2001, 33:1148-1153.
127. Enomoto N, Ikejima K, Bradford B, et al. Alcohol causes both tolerance and sensitization of rat Kupffer cells via mechanisms dependent on endotoxin. Gastroenterology 1998, 115:443-451.
128. Knolle PA, Gerken G Local control of the immune response in the liver. Immunol Rev 2000, 174:21-34.
129. McClain CJ, Cohen DA Increased tumor necrosis factor production by monocytes in alcoholic hepatitis. Hepatology 1989, 9:349-351.
130. Bird G, Sheron N, Goka AK, et al. Increased plasma tumour necrosis factor in severe alcoholic hepatitis. Ann Intern Med 1990, 112:917-920.
131. Natori S, Rust C, Stadheim LM, et al. Hepatocyte apoptosis is a pathologic feature of human alcoholic hepatitis. J Hepatol 2001, 34:248-253.
132. Day CP Apoptosis in alcoholic hepatitis: a novel therapeutic target?. [comment] J Hepatol 2001, 34:330-333.
133. Pessayre D, Fromenty B. NASH: a mitochondrial disease. J Hepatol 2005, 42:928-940.
134. Nechushtan A, Smith CL, Lamensforf I, et al. Bax and Bak coalesce into novel mitochondria-associated clusters during apoptosis. J Cell Biol 2001, 153:1265-1276.
135. Kirkland RA, Windelborn JA, Kasprzak JM, Franklin JL A Bax-induced pro-oxidant state is critical for cytochrome c release during programmed neuronal death. J Neurosci 2002, 22:6480-6490.
136. Matsumaru K, Ji C, Kaplowitz N. Mechanisms for sensitization to TNF-induced apoptosis by acute glutathione depletion in murine hepatocytes. Hepatology 2003, 37:1425-1434.
137. Crispe IN, Mehal WZ Strange brew. T cells in the liver. Immunol Today 1996, 17:522-525.
138. Laso FJ, Madruga JI, Giron JA, et al. Decreased natural killer cytotoxic activity in chronic alcoholism is associated with alcohol liver disease but not active ethanol consumption. Hepatology 1997, 25:1096-1100.
139. Minagawa M, Deng Q, Liu ZX, et al. Activated natural killer T cells induce liver injury by Fas and tumor necrosis factor-alpha during alcohol consumption. Gastroenterology 2004, 126:1387-1399.
140. Pruett SB, Schwab C, Zheng Q, Fan R Suppression of innate immunity by acute ethanol administration: a global perspective and a new mechanism beginning with inhibition of signaling through TLR3. J Immunol 2004, 173:2715-2724.
141. Mathurin P, Duchatelle V, Ramond MJ, et al. Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterology 1996, 110:1847-1853.
142. Zylberberg H, Fontaine H, Thepot V, et al. Triggering of acute alcoholic hepatitis by alpha-interferon therapy. J Hepatol 1999, 30:722-725.
143. Chedid A, Mendenhall CL, Moritz TE, et al. Cell-mediated hepatic injury in alcoholic liver disease. Veterans Affairs Cooperative Study Group 275. Gastroenterology 1993, 105:254-266.
144. Burt AD, Anthony RS, Hislop WS, et al. Liver membrane antibodies in alcoholic liver disease: 1. prevalence and immunoglobulin class. Gut 1982, 23:221-225.
145. Trevisan A, Cavigli R, Melocni R, et al. Detection of immunoglobulins G and A on the cell membrane of hepatocytes from patients with alcoholic liver disease. J Clin Pathol 1983, 36:530-534.
146. Van Pelt FN, Kenna JG Formation of trifluoroacetylated protein antigens in cultured rat hepatocytes exposed to halothane in vitro. Biochem Pharmacol 1994, 48:461-471.
147. Gut J, Christen U, Frey N, et al. Molecular mimicry in halothane hepatitis: biochemical and structural characterization of lipoylated autoantigens. Toxicology 1995, 97:199-224.
148. Eliasson E, Kenna JG Cytochrome P450 2E1 is a cell surface autoantigen in halothane hepatitis. Mol Pharmacol 1996, 50:573-582.
149. Homberg JC, Andre C, Abuaf N A new anti-liver-kidney microsome antibody (anti-LKM2) in tienilic acid-induced hepatitis. Clin Exp Immunol 1984, 55:561-570.
150. Beaune P, Dansette PM, Mansuy D, et al. Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug. Proc Natl Acad Sci USA 1987, 84:551-555.
151. Israel Y, Hurwitz E, Niemela O, Arnon R. Monoclonal and polyclonal antibodies against acetaldehyde-containing epitopes in acetaldehyde-protein adducts. Proc Natl Acad Sci USA 1986, 83:7923-7927.
152. Hoerner M, Behrens UJ, Worner T, Lieber CS Humoral immune response to acetaldehyde adducts in alcoholic patients. Res Commun Chem Pathol Pharmacol 1986, 54:3-12.
153. Lin RC, Smith RS, Lumeng L Detection of a protein-acetaldehyde adduct in the liver of rats fed alcohol chronically. J Clin Invest 1988, 81:615-619.
154. Nicholls RM, Fowles LF, Worrall S, et al. Distribution and turnover of acetaldehyde-modified proteins in liver and blood of ethanol-fed rats. Alcohol Alcoholism 1994, 29:149-157.
155. Niemela O, Juvonen T, Parkkila S. Immunohistochemical demonstration of acetaldehyde-modified epitopes in human liver after alcohol consumption. J Clin Invest 1991, 87:1367-1374.
156. Holstege A, Bedossa P, Pynard T, et al. Acetaldehyde-modified epitopes in liver biopsy specimens of alcoholic and nonalcoholic patients: localization and association with progression of liver fibrosis. Hepatology 1994, 19:367-374.
157. Worrall S, De Jersey J, Shanley BC, Wilce PA Antibodies against acetaldehyde-modified epitopes: presence in alcoholic, non-alcoholic liver disease and control subjects. Alcohol Alcohlism 1990, 25:509-517.
158. Niemela O, Klanjer F, Orrego H, et al. Antibodies against acetaldehyde-modified protein epitopes in human alcoholics. Hepatology 1987, 7:1210-1214.
159. Viitala K, Israel Y, Blake JE, Niemela O Serum IgA, IgG, and IgM antibodies directed against acetaldehyde-derived epitopes: relationship to liver disease severity and alcohol consumption. Hepatology 1997, 25:1418-1424.
160. Albano E, Tomasi A, Persson JO, et al. Role of ethanol-inducible cytochrome P450 (P450IIE1) in catalysing the free radical activation of aliphatic alcohols. Biochem Pharmacol 1991, 41:1895-1902.
161. Moncada C, Torres V, Varghese G, et al. Ethanol-derived immunoreactive species formed by free radical mechanisms. Mol Pharmacol 1994, 46:786-791.
162. Clot P, Bellomo G, Tabone M, et al. Detection of antibodies against proteins modified by hydroxyethyl free radicals in patients with alcoholic cirrhosis. Gastroenterology 1995, 108:201-207.
163. Niemela O, Parkkila S, Yla-Hertuala S, et al. Covalent protein adducts in the liver as a result of ethanol metabolism and lipid peroxidation. Lab Invest 1994, 70:537-546.
164. Mottaran E, Stewart SF, Rolla R, et al. Lipid peroxidation contributes to immune reactions associated with alcoholic liver disease. Free Radical Biol Med 2002, 32:38-45.
165. Tuma DJ, Thiele GM, Xu D, et al. Acetaldehyde and malondialdehyde react together to generate distinct protein adducts in the liver during long-term ethanol administration. Hepatology 1996, 23:872-880.
166. Rolla R, Vay D, Mottaran E, et al. Detection of circulating antibodies against malondialdehyde-acetaldehyde adducts in patients with alcohol-induced liver disease. Hepatology 2000, 31:878-884.
167. McFarlane IG, Wojcicka BM, Zucker GM, et al. Purification and characterization of human liver-specific membrane lipoprotein (LSP). Clin Exp Immunol 1977, 27:381-390.
168. Kakumu S, Arakawa Y, Goji H, et al. Occurrence and significance of antibody to liver-specific membrane lipoprotein by double-antibody immunoprecipitation method in sera of patients with acute and chronic liver diseases. Gastroenterology 1979, 76:665-672.
169. Perperas A, Tsantoulas D, Portmann B, et al. Autoimmunity to a liver membrane lipoprotein and liver damage in alcoholic liver disease. Gut 1981, 22:149-152.
170. Hopf U, Meyer zum Buschenfelde KH, Arnold W Detection of a liver-membrane autoantibody in HBsAg-negative chronic active hepatitis. N Engl J Med 1976, 294:578-582.
171. Rolla R, Vay D, Mottaran E, et al. Antiphospholipid antibodies associated with alcoholic liver disease specifically recognise oxidised phospholipids. Gut 2001, 49:852-859.
172. Clot P, Albano E, Eliasson E, et al. Cytochrome P4502E1 hydroxyethyl radical adducts as the major antigen in autoantibody formation among alcoholics. Gastroenterology 1996, 111:206-216.
173. Lytton SD, Helander A, Zhang-Gouillon ZQ, et al. Autoantibodies against cytochromes P-4502E1 and P-4503A in alcoholics. Mol Pharmacol 1999, 55:223-233.
174. Vidali M, Stewart SF, Rolla R, et al. Genetic and epigenetic factors in autoimmune reactions toward cytochrome P4502E1 in alcoholic liver disease. Hepatology 2003, 37:410-419.
175. Cochrane AM, Moussouros A, Portmann B, et al. Lymphocyte cytotoxicity for isolated hepatocytes in alcoholic liver disease. Gastroenterology 1977, 72:918-923.
176. Clot P, Parola M, Bellomo G, et al. Plasma membrane hydroxyethyl radical adducts cause antibody-dependent cytotoxicity in rat hepatocytes exposed to alcohol [see comments]. Gastroenterology 1997, 113:265-276.
177. Stewart SF, Vidali M, Day CP, et al. Oxidative stress as a trigger for cellular immune responses in patients with alcoholic liver disease. Hepatology 2004, 39:197-203.
178. Friedman SL Cellular sources of collagen and regulation of collagen production in liver. Semin Liver Dis 1990, 10:20-29.
179. Gressner AM The cell biology of liver fibrogenesis - an imbalance of proliferation, growth arrest and apoptosis of myofibroblasts. Cell Tissue Res 1998, 292:447-452.
180. Maher JJ, McGuire RF Extracellular matrix gene expression increases preferentially in rat lipocytes and sinusoidal endothelial cells during hepatic fibrosis in vivo. J Clin Invest 1990, 86:1641-1648.
181. Safadi R, Ohta M, Alvarez CE, et al. Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. Gastroenterology 2004, 127:870-882.
182. Holt K, Bennett M, Chojkier M. Acetaldehyde stimulates collagen and noncollagen protein production by human fibroblasts. Hepatology 1984, 4:843-848.
183. Ma X, Svegliati-Baroni G, Poniachik J, et al. Collagen synthesis by liver stellate cells is released from its normal feedback regulation by acetaldehyde-induced modification of the carboxyl-terminal propeptide of procollagen. Alcohol Clin Exp Res 1997, 21:1204-1211.
184. Nieto N, Friedman SL, Cederbaum AI Cytochrome P450 2E1-derived reactive oxygen species mediate paracrine stimulation of collagen I protein synthesis by hepatic stellate cells. J Biol Chem 2002, 277:9853-9864.
185. Canbay A, Higuchi H, Bronk SF, et al. Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology 2002, 123:1323-1330.
186. Canbay A, Taimr P, Torok N, et al. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest 2003, 83:655-663.
187. 2, and PAF. J Clin Invest 1998, 101:890-898.
188. Nair S, Mason A, Eason J, et al. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis?. [erratum appears in Hepatology 2002, 36:774.
189. Hepatology 2002, 36:150-155.
190. Marnett LJ Oxy radicals, lipid peroxidation and DNA damage. Toxicology 2002, 181-182:219-222.
191. Fink SP, Reddy GR, Marnett LJ Mutagenicity in Escherichia coli of the major DNA adduct derived from the endogenous mutagen malondialdehyde. Proc Natl Acad Sci USA 1997, 94:8652-8657.
192. Ji C, Rouzer CA, Marnett LJ, Pietenpol JA Induction of cell cycle arrest by the endogenous product of lipid peroxidation, malondialdehyde. Carcinogenesis 1998, 19:1275-1283.
193. Roskams T, Yang SQ, Koteish A, et al. Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease. Am J Pathol 2003, 163:1301-1311.
194. Kuper H, Tzonou A, Kaklamani E, et al. Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int J Cancer 2000, 85:498-502.
195. Bulatao-Jayme J, Almero EM, Castro MC, et al. A case-control dietary study of primary liver cancer risk from aflatoxin exposure. Int J Epidemiol 1982, 11:112-119.
196. Garro AJ, Seitz HK, Lieber CS Enhancement of dimethylnitrosamine metabolism and activation to a mutagen following chronic ethanol consumption. Cancer Res 1981, 41:120-124.
197. Chung J, Liu C, Smith DE, et al. Restoration of retinoic acid concentration suppresses ethanol-enhanced c-Jun expression and hepatocyte proliferation in rat liver. Carcinogenesis 2001, 22:1213-1219.
198. Wang XD, Liu C, Chung J, et al. Chronic alcohol intake reduces retinoic acid concentration and enhances AP-1 ( c-Jun and c-Fos) expression in rat liver. Hepatology 1998, 28:744-750.
199. Shen L, Fang J, Qiu D, et al. Correlation between DNA methylation and pathological changes in human hepatocellular carcinoma. HepatoGastroenterology 1998, 45:1753-1759.
200. Zapisek WF, Cronin GM, Lyn-Cook BD, Poirier LA The onset of oncogene hypomethylation in the livers of rats fed methyl-deficient, amino acid-defined diets. Carcinogenesis 1992, 13:1869-1872.
201. Gallucci RM, Pfister LJ, Meadows GG Effects of ethanol consumption on enriched natural killer cells from C57BL/6 mice. Alcohol Clin Exp Res 1994, 18:625-631.
202. Miyakawa H, Sato C, Izumi N, et al. Hepatitis C virus infection in alcoholic liver cirrhosis in Japan: its contribution to the development of hepatocellular carcinoma. Alcohol Alcohol Suppl 1993, 1A:85-90.
203. Bellentani S, Saccoccio G, Costa G, et al. Drinking habits as cofactors of risk for alcohol induced liver damage The Dionysos Study Group [see comments]. Gut 1997, 41:845-850.
204. Lelbach WK Cirrhosis in the alcoholic and its relation to the volume of alcohol abuse. Ann NY Acad Sci 1975, 252:85-105.
205. Krasner N, Davis M, Portmann B, Williams R. Changing pattern of alcoholic liver disease in Great Britain: relation to sex and signs of autoimmunity. Br Med J 1977, 1:1497-1500.
206. Becker U, Deis A, Sorensen TI, et al. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology 1996, 23:1025-1029.
207. Becker U, Gronbaek M, Johansen D, Sorensen TI Lower risk for alcohol-induced cirrhosis in wine drinkers [see comment]. Hepatology 2002, 35:868-875.
208. Nanji AA, French SW Relationship between pork consumption and cirrhosis. Lancet 1985, 1:681-683.
209. Rotily M, Durbec JP, Berthezene P, Sarles H Diet and alcohol in liver cirrhosis: a case-control study. Eur J Clin Nutr 1990, 44:595-603.
210. Raynard B, Balian B, Fallik D, et al. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology 2002, 35:635-638.
211. Enomoto N, Takei Y, Kitamura T, et al. Estriol enhances lipopolysaccharide-induced increases in nitric oxide production by Kupffer cells via mechanisms dependent on endotoxin. Alcohol Clin Exp Res 2002, 26(suppl):66S-69S.
212. Hrubec Z, Omenn GS Evidence of genetic predisposition to alcoholic cirrhosis and psychosis: twin concordances for alcoholism and its biological end points by zygosity among male veterans. Alcoholism Clin Exp Res 1981, 5:207-215.
213. Stinson FS, Grant BF, Dufour MC The critical dimension of ethnicity in liver cirrhosis mortality statistics. Alcohol Clin Exp Res 2001, 25:1181-1187.
214. Caetano R, Clark CL Trends in alcohol-related problems among whites, blacks, and Hispanics: 1984-1995. Alcohol Clin Exp Res 1998, 22:534-538.
215. Daly A, Day CP Candidate gene case-control association studies: advantages and pitfalls. Br J Clin Pharmacol 2001, 52:489-499.
216. Day CP, Leathart JB, Daly AK Genetic evidence that fatty liver is involved in the pathogenesis of advanced alcoholic liver disease. Hepatology 2002, 36(suppl 1):16.
217. Chao YC, Young TH, Tang HS, Hsu CT Alcoholism and alcoholic organ damage and genetic polymorphisms of alcohol metabolizing enzymes in Chinese patients. Hepatology 1997, 25:112-117.
218. Chao YC, Wang LS, Hsieh TY, et al. Chinese alcoholic patients with esophageal cancer are genetically different from alcoholics with acute pancreatitis and liver cirrhosis. Am J Gastroenterol 2000, 95:2958-2964.
219. Tanaka F, Shiratori Y, Yokosuka F, et al. High incidence of ADH2 *1/ALDH2 *1 genes among Japanese alcohol dependents and patients with alcoholic liver disease. Hepatology 1996, 23:234-239.
220. Osier M, Pakstis AJ, Kidd JR, et al. Linkage disequilibrium at the ADH2 and ADH3 loci and risk of alcoholism. Am J Hum Genet 1999, 64:1147-1157.
221. Borras E, Coutelle C, Rosell A, et al. Genetic polymorphism of alcohol dehydrogenase in Europeans: the ADH2 *2 allele decreases the risk for alcoholism and is associated with ADH3 *1. Hepatology 2000, 31:984-989.
222. Grove J, Brown AS, Daly AK, et al. The RsaI polymorphism of CYP2E1 and susceptibility to alcoholic liver disease in Caucasians: effect on age of presentation and dependence on alcohol dehydrogenase genotype. Pharmacogenetics 1998, 8:335-342.
223. Grove J, Daly AK, Burt AD, et al. Heterozygotes for HFE mutations have no increased risk of advanced alcoholic liver disease. Gut 1998, 43:262-266.
224. Degoul F, Sutton A, Mansouri A, et al. Homozygosity for alanine in the mitochondrial targeting sequence of superoxide dismutase and risk for severe alcoholic liver disease. Gastroenterology 2001, 120:1468-1474.
225. Stewart SF, Leathart JB, Chen Y, et al. Valine-alanine manganese superoxide dismutase polymorphism is not associated with alcohol-induced oxidative stress or liver fibrosis. Hepatology 2002, 36:1355-1360.
226. Baldini M, Lohman IC, Halonen M, et al. A polymorphism * in the 5' flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E. Am J Respir Cell Mol Biol 1999, 20:976-983.
227. Leathart JB, Day CP, Daly AK No association between functional SNPs in the endotoxin receptors CD14 and TLR4 and alcoholic liver disease (ALD): is endotoxin important in the pathogenesis of ALD in humans?. Hepatology 2001, 34:459A.
228. Arbour NC, Lorenz E, Schutte BC, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000, 25:187-191.
229. Grove J, Daly AK, Bassendine MF, Day CP Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis. Hepatology 1997, 26:143-146.
230. Grove J, Daly AK, Bassendine MF, et al. Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease [see comment]. Gut 2000, 46:540-545.
231. Waterhouse P, Marengere LE, Mittrucker HW, Mak TW CTLA-4, a negative regulator of T-lymphocyte activation. Immunol Rev 1996, 153:183-207.
232. Ueda H, Howson JM, Epsosito L, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003, 423:506-511.
233. Valenti L, De Feo T, Fracanzani AL, et al. Cytotoxic T-lymphocyte antigen-4 A49G polymorphism is associated with susceptibility to and severity of alcoholic liver disease in Italian patients. Alcohol Alcohol 2004, 39:276-280.
234. Baptista A. Alcoholic liver disease: morphological manifestations. Review by an international group. Lancet 1981, 1:707-711.
235. MacSween RN, Burt AD Histologic spectrum of alcoholic liver disease. Semin Liver Dis 1986, 6:221-232.
236. Levin DM, Baker AL, Riddell RH, et al. Nonalcoholic liver disease. Overlooked causes of liver injury in patients with heavy alcohol consumption. Am J Med 1979, 66:429-434.
237. Morgan MY, Sherlock S, Scheuer PJ Acute cholestasis, hepatic failure, and fatty liver in the alcoholic. Scand J Gastroenterol 1978, 13:299-303.
238. Wu A, Slavin G, Levi AJ Elevated serum gamma-glutamyl-transferase (transpeptidase) and histological liver damage in alcoholism. Am J Gastroenterol 1976, 65:318-323.
239. Rosalki SB, Tarlow D, Rau D Plasma gamma-glutamyl transpeptidase elevation in patients receiving enzyme-inducing drugs. Lancet 1971, 2:376-377.
240. Drum DE, Goldman PA, Jankowski CB Elevation of serum uric acid as a clue to alcohol abuse. Arch Intern Med 1981, 141:477-479.
241. Storey EL, Anderson GJ, Mack U, et al. Desialylated transferrin as a serological marker of chronic excessive alcohol ingestion. Lancet 1987, 1:1292-1294.
242. Buffet C, Chaput JC, Albuisson F, et al. [Macrocytosis in chronic alcoholic hepatitis (author's translation).]. Arch Fr Maladies Appareil Digest 1975, 64:309-315.
243. Skude G, Wadstein J. Amylase, hepatic enzymes and bilirubin in serum of chronic alcoholics. Acta Med Scand 1977, 201:53-58.
244. Clermont RJ, Chalmers TC The transaminase tests in liver disease. Medicine 1967, 46:197-207.
245. Angulo P, Keach JC, Batts KP, Lindor KD Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999, 30:1356-1362.
246. Bailey RJ, Krasner N, Eddleston AL, et al. Histocompatibility antigens, autoantibodies, and immunoglobulins in alcoholic liver disease. Br Med J 1976, 2:727-729.
247. Bell H, Raknerud N, Orjasaeter H, Haug E. Serum procollagen III peptide in alcoholic and other chronic liver diseases. Scand J Gastroenterol 1989, 24:1217-1222.
248. Bruguera M, Bordas JM, Rodes J Asymptomatic liver disease in alcoholics. Arch Pathol Lab Med 1977, 101:644-647.
249. Van Waes L, Lieber CS Early perivenular sclerosis in alcoholic fatty liver: an index of progressive liver injury. Gastroenterology 1977, 73:646-650.
250. Uchida T, Kao H, Quispe-Sjogren M, Peters RL Alcoholic foamy degeneration - a pattern of acute alcoholic injury of the liver. Gastroenterology 1983, 84:683-692.
251. Rubin E, Lieber CS Alcohol-induced hepatic injury in nonalcoholic volunteers. N Engl J Med 1968, 278:869-876.
252. Devenyi P, Rutherdale J, Sereny G, Olin JS Clinical diagnosis of alcoholic fatty liver. Am J Gastroenterol 1970, 54:597-602.
253. Leevy CM Fatty liver: a study of 270 patients with biopsy proven fatty liver and a review of the literature. Medicine 1962, 41:249-276.
254. Hislop WS, Bouchier IA, Allan JG, et al. Alcoholic liver disease in Scotland and northeastern England: presenting features in 510 patients. Q J Med 1983, 52:232-243.
255. Hardison WG, Lee FI Prognosis in acute liver disease of the alcoholic patient. N Engl J Med 1966, 275:61-66.
256. Mendenhall CL Alcohol-related diseases in gastroenterology 1985, Springer Verlag, Berlin.
257. Gluud C, Henriksen JH, Nielsen G Prognostic indicators in alcoholic cirrhotic men. Hepatology 1988, 8:222-227.
258. Orrego H, Israel Y, Blake JE, Medline A Assessment of prognostic factors in alcoholic liver disease: toward a global quantitative expression of severity. Hepatology 1983, 3:896-905.
259. Carithers RL, Herlong HF, Diehl AM, et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med 1989, 110:685-690.
260. Forrest EH, Morris JM, Stewart SF, Day CP The Glasgow Alcoholic Hepatitis Score identifies patients likely to benefit from corticosteroids. Gut 2004, 53(suppl 3):A13.
261. Alexander JF, Lischner MW, Galambos JT Natural history of alcoholic hepatitis. II. The long-term prognosis. Am J Gastroenterol 1971, 56:515-525.
262. Goldberg S, Mendenhall C, Anderson S, et al. VA cooperative study on alcoholic hepatitis. IV The significance of clinically mild alcoholic hepatitis - describing the population with minimal hyperbilirubinemia. Am J Gastroenterol 1986, 81:1029-1034.
263. Pares A, Caballeria J, Bruguera M, et al. Histological course of alcoholic hepatitis. Influence of abstinence, sex and extent of hepatic damage. J Hepatol 1986, 2:33-42.
264. Rubin E, Kus S, Popper H. Pathogenesis of post-necrotic cirrhosis in alcoholics. Arch Pathol 1962, 73:288-299.
265. Gines P, Quintero E, Arroyo V, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987, 7:122-128.
266. Mendenhall CL, Gartside PS, Roselle GA, et al. Longevity among ethnic groups in alcoholic liver disease. Alcohol Alcoholism 1989, 24:11-19.
267. Saunders JB, Walters JR, Davies AP, Paton A A 20-year prospective study of cirrhosis. Br Med J Clin Res Ed 1981, 282:263-266.
268. D'Amico G, Morabito A, Pagliaro L, Marubini E Survival and prognostic indicators in compensated and decompensated cirrhosis. Digest Dis Sci 1986, 31:468-475.
269. Powell WJ, Klatskin G Duration of survival in patients with Laennec's cirrhosis. Influence of alcohol withdrawal, and possible effects of recent changes in general management of the disease. Am J Med 1968, 44:406-420.
270. Orrego H, Blake JE, Blendis LM, Medline A Prognosis of alcoholic cirrhosis in the presence and absence of alcoholic hepatitis. Gastroenterology 1987, 92:208-214.
271. Lee FI Cirrhosis and hepatoma in alcoholics. Gut 1966, 7:77-85.
272. Pessione F, Ramond MJ, Peters L, et al. Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence. Liver Int 2003, 23:45-53.
273. Scott J, Burns J, Flower EA Histological analysis of parotid and submandibular glands in chronic alcohol abuse: a necropsy study. J Clin Pathol 1988, 1:837-840.
274. Dutta SK, Dukehart M, Narang A, Latham PS Functional and structural changes in parotid glands of alcoholic cirrhotic patients. Gastroenterology 1989, 96:510-518.
275. Larato DC Oral tissue changes in the chronic alcoholic. J Periodontol 1972, 43:772-773.
276. Erisen L, Basut O, Tezel I, et al. Regional epidemiological features of lip, oral cavity, and oropharyngeal cancer. J Environ Pathol Toxicol Oncol 1996, 15:225-229.
277. Vakevainen S, Tillonen J, Agarwal DP, et al. High salivary acetaldehyde after a moderate dose of alcohol in ALDH2-deficient subjects: strong evidence for the local carcinogenic action of acetaldehyde. Clin Exp Res 2000, 24:873-877.
278. Hogan WJ, Viegas de Andrade SR, Winship DH Ethanol-induced acute esophageal motor dysfunction. J Appl Physiol 1972, 32:755-760.
279. Knauer CM Mallory-Weiss syndrome. Characterization of 75 Mallory-Weiss lacerations in 528 patients with upper gastrointestinal hemorrhage. Gastroenterology 1976, 71:5-8.
280. Launoy G, Milan CH, Faivre J, et al. Alcohol, tobacco and oesophageal cancer: effects of the duration of consumption, mean intake and current and former consumption. Br J Cancer 1997, 75:1389-1396.
281. Teyssen S, Gonzalez-Calero G, Schimiczek M, Singer MV Maleic acid and succinic acid in fermented alcoholic beverages are the stimulants of gastric acid secretion. J Clin Invest 1999, 103:707-713.
282. Hauge T, Persson J, Kjerstadius T. Helicobacter pylori, active chronic antral gastritis, and gastrointestinal symptoms in alcoholics. Alcoholism Clin Exp Res 1994, 18:886-888.
283. Piper DW, Nasiry R, McIntosh J, et al. Smoking, alcohol, analgesics, and chronic duodenal ulcer. A controlled study of habits before first symptoms and before diagnosis. Scand J Gastroenterol 1984, 19:1015-1021.
284. Keshavarzian A, Iber FL, Dangleis MD, Cornish R Intestinal-transit and lactose intolerance in chronic alcoholics. Am J Clin Nutr 1986, 44:70-76.
285. Rubin E, Rybak BJ, Lindenbaum J, et al. Ultrastructural changes in the small intestine induced by ethanol. Gastroenterology 1972, 63:801-814.
286. Hermos JA, Adams WH, Liu YK, et al. Mucosa of the small intestine in folate-deficient alcoholics. Ann Intern Med 1972, 76:957-965.
287. Perlow W, Baraona E, Lieber CS Symptomatic intestinal disaccharidase deficiency in alcoholics. Gastroenterology 1977, 72:680-684.
288. Robinson GM, Orrego H, Israel Y, et al. Low-molecular-weight polyethylene glycol as a probe of gastrointestinal permeability after alcohol ingestion. Digest Dis Sci 1981, 26:971-977.
289. Buell MG, Beck IT Effect of ethanol on jejunal regional blood flow in the rabbit. Gastroenterology 1983, 84:81-89.
290. Seal CJ, Ford CL, Day CP Alcoholism: effects on nutritional status. Encyclopedia of human nutrition 1998, Academic Press, London. N. Fallon (Ed.).
291. Bouchoucha M, Nalpas B, Berger M, et al. Recovery from disturbed colonic transit time after alcohol withdrawal. Dis Colon Rectum 1991, 34:111-114.
292. Wilson JS, Pirola RC The drinker's pancreas: molecular mechanisms emerge. Gastroenterology 1997, 113:355-358.
293. Braganza JM The pathogenesis of chronic pancreatitis. Q J Med 1996, 89:243-250.
294. Kloppel G, Maillet B. Chronic pancreatitis: evolution of the disease. HepatoGastroenterology 1991, 38:408-412.
295. Mukamal KJ, Conigrave KM, Mittleman MA, et al. Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men. N Engl J Med 2003, 348:109-118.
296. Marmot M, Brunner E. Alcohol and cardiovascular disease: the status of the U shaped curve. Br Med J 1991, 303:565-568.
297. Ashley MJ, Rankin JG Hazardous alcohol consumption and diseases of the circulatory system. J Stud Alcohol 1980, 41:1040-1070.
298. Saunders JB, Beevers DG, Paton A Alcohol-induced hypertension. Lancet 1981, 2:653-656.
299. Puddey IB, Vandongen R, Beilin LJ Pressor effect of alcohol. Lancet 1985, 2:1119-1120.
300. MacMahon SW, Norton RN Alcohol and hypertension: implications for prevention and treatment. Ann Intern Med 1986, 105:124-126.
301. Klatsky AL, Friedman GD, Armstrong MA The relationships between alcoholic beverage use and other traits to blood pressure: a new Kaiser Permanente study. Circulation 1986, 73:628-636.
302. Paulin JM, Simpson FO, Waal-Manning HJ Alcohol consumption and blood pressure in a New Zealand community study. NZ Med J 1985, 98:425-428.
303. Rimm EB, Giovannucci EL, Willett WC, et al. Prospective study of alcohol consumption and risk of coronary disease in men. Lancet 1991, 338:464-468.
304. Lazarus NB, Kaplan GA, Cohen RD, Leu DJ Change in alcohol consumption and risk of death from all causes and from ischaemic heart disease. Br Med J 1991, 303:553-556.
305. Friedman GD, Klatsky AL Is alcohol good for your health?. N Engl J Med 1993, 329:1882-1883.
306. Gaziano JM, Buring JE, Breslow JL, et al. Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction. N Engl J Med 1993, 329:1829-1834.
307. Haut MJ, Cowan DH The effect of ethanol on hemostatic properties of human blood platelets. Am J Med 1974, 56:22-33.
308. Rubin R. Ethanol interferes with collagen-induced platelet activation by inhibition of arachidonic acid mobilization. Arch Biochem Biophys 1989, 270:99-113.
309. Taylor JR Alcohol and strokes. N Engl J Med 1982, 306:1111.
310. Stampfer MJ, Colditz GA, Willett WC, et al. A prospective study of moderate alcohol consumption and the risk of coronary disease and stroke in women. N Engl J Med 1988, 319:267-273.
311. Wilkins MR, Kendall MJ Stroke affecting young men after alcoholic binges. Br Med J (Clin Res Ed) 1985, 291:1342.
312. Donahue RP, Abbott RD, Reed DM, Yano K Alcohol and hemorrhagic stroke. The Honolulu Heart Program. JAMA 1986, 255:2311-2314.
313. Schenk EA, Cohen J The heart in chronic alcoholism. Clinical and pathologic findings. Pathol Microbiol (Basel) 1970, 35:96-104.
314. Urbano-Marquez A, Estruch R, Navarro-Lopez F, et al. The effects of alcoholism on skeletal and cardiac muscle. N Engl J Med 1989, 320:409-415.
315. Jacob AJ, McLaren KM, Boon NA Effects of abstinence on alcoholic heart muscle disease. Am J Cardiol 1991, 68:805-807.
316. Koskinen P, Kupari M. Alcohol and cardiac arrhythmias. Br Med J 1992, 304:1394-1395.
317. Cohen EJ, Klatsky AL, Armstrong MA Alcohol use and supraventricular arrhythmia. Am J Cardiol 1988, 62:971-973.
318. Greenspon AJ, Schaal SF The "holiday heart": electrophysiologic studies of alcohol effects in alcoholics. Ann Intern Med 1983, 98:135-139.
319. Wannamethee G, Shaper AG Alcohol and sudden cardiac death. Br Heart J 1992, 68:443-448.
320. Day CP, James OF, Butler TJ, Campbell RW QT prolongation and sudden cardiac death in patients with alcoholic liver disease [comment]. Lancet 1993, 341:1423-1428.
321. Butterworth RF Pathophysiology of alcoholic brain damage: synergistic effects of ethanol, thiamine deficiency and alcoholic liver disease. Metab Brain Dis 1995, 10:1-8.
322. Charness ME Brain lesions in alcoholics. Alcohol Clin Exp Res 1993, 17:2-11.
323. Orgogozo JM, Dartigues JF, Lafont S, et al. Wine consumption and dementia in the elderly: a prospective community study in the Bordeaux area. Rev Neurol (Paris) 1997, 153:185-192.
324. Duncan G, Johnson RH, Lambie DG, Whiteside EA Evidence of vagal neuropathy in chronic alcoholics. Lancet 1980, 2:1053-1057.
325. Barter F, Tanner AR Autonomic neuropathy in an alcoholic population. Postgrad Med J 1987, 63:1033-1036.
326. Thuluvath PJ, Triger DR Autonomic neuropathy and chronic liver disease. Q J Med 1989, 72:737-747.
327. Mohamed R, Forsey PR, Davies MK, Neuberger JM Effect of liver transplantation on QT interval prolongation and autonomic dysfunction in end-stage liver disease. Hepatology 1996, 23:1128-1134.
328. Abel EL, Sokol RJ A revised conservative estimate of the incidence of FAS and its economic impact. Alcohol Clin Exp Res 1991, 15:514-524.
329. Longnecker MP, Enger SM Epidemiologic data on alcoholic beverage consumption and risk of cancer. Clin Chim Acta 1996, 246:121-141.
330. Smith-Warner SA, Spiegelman D, Yaun SS, et al. Alcohol and breast cancer in women: a pooled analysis of cohort studies. JAMA 1998, 279:535-540.
331. Hamajima N, Hirose K, Tajima K, et al. Alcohol, tobacco and breast cancer - collaborative reanalysis of individual data from 53 epidemiological studies, including 58 515 women with breast cancer and 95 067 women without the disease. Br J Cancer 2002, 87:1234-1245.
332. Zieve L. Jaundice, hyperlipemia and hemolytic anemia: a heretofore unrecognized syndrome associated with alcoholic fatty liver and cirrhosis. Ann Intern Med 1958, 48:471-496.
333. Nelson S, Kolls JK Alcohol, host defense and society. Nature Reviews. Immunology 2002, 2:205-209.
334. Longnecker MP Alcohol consumption and risk of cancer in humans: an overview. Alcohol 1995, 12:87-96.
335. Patel M, Keshavarzian A, Kottapalli V, et al. Human neutrophil functions are inhibited in vitro by clinically relevant ethanol concentrations. Alcoholism Clin Exp Res 1996, 20:275-283.
336. Stoltz DA, Zhang P, Nelson S, et al. Ethanol suppression of the functional state of polymorphonuclear leukocytes obtained from uninfected and simian immunodeficiency virus infected rhesus macaques. Alcoholism Clin Exp Res 1999, 23:878-884.
337. Hill DB, Devalaraja R, Joshi-Barve S, et al. Antioxidants attenuate nuclear factor-kappa B activation and tumor necrosis factor-alpha production in alcoholic hepatitis patient monocytes and rat Kupffer cells, in vitro. Clin Biochem 1999, 32:563-570.
338. McClain CJ, Hill DB, Song Z, et al. Monocyte activation in alcoholic liver disease. Alcohol 2002, 27:53-61.
339. Silvain C, Patry C, Launay P, et al. Altered expression of monocyte IgA Fc receptors is associated with defective endocytosis in patients with alcoholic cirrhosis. Potential role for IFN-gamma. J Immunol 1995, 155:1606-1618.
340. Szabo G, Verma B, Catalano D. Selective inhibition of antigen-specific T lymphocyte proliferation by acute ethanol exposure: the role of impaired monocyte antigen presentation capacity and mediator production. J Leukocyte Biol 1993, 54:534-544.
341. Ewald SJ, Shao H Ethanol increases apoptotic cell death of thymocytes in vitro. Alcoholism Clin Exp Res 1993, 17:359-365.
342. Pruett SB, Han YC, Wu WJ A brief review of immunomodulation caused by acute administration of ethanol: involvement of neuroendocrine pathways. Alcohol Alcoholism 1994, 2(suppl):431-437.
343. Glassman AB, Bennett CE, Randall CL Effects of ethyl alcohol on human peripheral lymphocytes. Arch Pathol Lab Med 1985, 109:540-542.
344. Lindenbaum J, Hargrove RL Thrombocytopenia in alcoholics. Ann Intern Med 1968, 68:526-532.
345. Van Thiel DH, Lester R, Vaitukaitis J Evidence for a defect in pituitary secretion of luteinizing hormone in chronic alcoholic men. J Clin Endocrinol Metab 1978, 47:499-507.
346. Frajria R, Angeli A. Alcohol-induced pseudo-Cushing's syndrome. Lancet 1977, 1:1050-1051.
347. Peris P, Guanabens N, Pares A, et al. Vertebral fractures and osteopenia in chronic alcoholic patients. Calcif Tissue Int 1995, 57:111-114.
348. Peris P, Pares A, Guanabens N, et al. Bone mass improves in alcoholics after 2 years of abstinence. J Bone Miner Res 1994, 9:1607-1612.
349. Royal College of Physicians. Alcohol - can the NHS afford it? Royal College of Physicians Working Party Report, 2001;.
350. Wilk AI, Jensen NM, Havighurst TC Meta-analysis of randomized control trials addressing brief interventions in heavy alcohol drinkers. J Gen Intern Med 1997, 12:274-283.
351. Kadden RM Project MATCH: treatment main effects and matching results. Alcoholism Clin Exp Res 1996, 20(suppl):196A-197A.
352. O'Malley SS, Kaffe G, Chang RS, et al. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry 1992, 49:881-887.
353. Sass H, Soyka M, Mann K, Zieglgansberger W. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry 1996, 53:673-680.
354. Garbutt JC, West SL, Carey TS, et al. Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA 1999, 281:1318-1325.
355. Delgrange T, Khater J, Capron D, et al. [Effect of acute administration of acamprosate on the risk of encephalopathy and on arterial pressure in patients with alcoholic cirrhosis.]. Gastroenterol Clin Biol 1992, 16:687-691.
356. Chick J, Gough K, Falkowski W, et al. Disulfiram treatment of alcoholism. Br J Psychiatry 1992, 161:84-89.
357. Fuller RK, Branchey L, Brightwell DR, et al. Disulfiram treatment of alcoholism. A Veterans Administration cooperative study. JAMA 1986, 256:1449-1455.
358. Peachey JE A review of the clinical use of disulfiram and calcium carbimide in alcoholism treatment. J Clin Psychopharmacol 1981, 1:368-375.
359. Wodak AD, Saunders JB, Ewusi-Mensah I, et al. Severity of alcohol dependence in patients with alcoholic liver disease. Br Med J Clin Res Ed 1983, 287:1420-1422.
360. Day CP Moderate alcohol intake is not deleterious in patients with alcoholic liver disease. Hepatology 1996, 24:443A.
361. Maddrey WC, Boitnott JK, Bedine MS, et al. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978, 75:193-199.
362. Ramond MJ, Poynard T, Rueff B, et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med 1992, 326:507-512.
363. Ray A, Prefontaine KE Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. Proc Natl Acad Sci USA 1994, 91:752-756.
364. Ghosh S. Regulation of inducible gene expression by the transcription factor NF-kappaB. Immunol Res 1999, 19:183-189.
365. Reynolds T, Benhamon JP, Blake JE, et al. Treatment of alcoholic hepatitis. Gastroenterol Int 1989, 2:208-216.
366. Imperiale TF, McCullough AJ Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials. Ann Intern Med 1990, 113:299-307.
367. Daures JP, Peray P, Bories P, et al. [Corticoid therapy in the treatment of acute alcoholic hepatitis. Results of a metaanalysis.] Gastroenterol Clin Biol 1991, 15:223-228.
368. Christensen E, Gluud C. Glucocorticosteroids are not effective in alcoholic hepatitis. Am J Gastroenterol 1999, 94:3065-3066.
369. Mathurin P, Mendenhall CL, Carithers RL, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol 2002, 36:480-487.
370. Mathurin P, Abdelnour M, Ramond MJ, et al. Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. Hepatology 2003, 38:1363-1369.
371. Strieter RM, Remick DG, Ward PA, et al. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun 1988, 155:1230-1236.
372. Akriviadis E, Botla R, Briggs W, et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000, 119:1637-1648.
373. Mutimer DJ, Burra P, Neuberger JM, et al. Managing severe alcoholic hepatitis complicated by renal failure. Q J Med 1993, 86:649-656.
374. Mendenhall CL, Anderson S, Weesner RE, et al. Protein-calorie malnutrition associated with alcoholic hepatitis. Veterans Administration cooperative study group on alcoholic hepatitis. Am J Med 1984, 76:211-222.
375. Nasrallah SM, Galambos JT Aminoacid therapy of alcoholic hepatitis. Lancet 1980, 2:1276-1277.
376. Diehl AM, Boitnott JK, Herlong HF, et al. Effect of parenteral amino acid supplementation in alcoholic hepatitis. Hepatology 1985, 5:57-63.
377. Cabre E, Gonzalez-Huix F, Abad-Lacruz A, et al. Effect of total enteral nutrition on the short-term outcome of severely malnourished cirrhotics. A randomized controlled trial. Gastroenterology 1990, 98:715-720.
378. Cabre E, Rodriguez-Iglesias P, Caballeria J, et al. Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial. Hepatology 2000, 32:36-42.
379. Wenzel G, Kuklinski B, Ruhlmann C, Ehrhardt D. [Alcohol-induced toxic hepatitis - a "free radical" associated disease. Lowering fatality by adjuvant antioxidant therapy] Z Gesamte Inn Med Grenzgebiete 1993, 48:490-496.
380. Phillips M, Curtis H, Portmann B, et al. Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis: a randomised trial. Hepatology 2001, 34:250A.
381. Fang JW, Bird GL, Nakamura T, et al. Hepatocyte proliferation as an indicator of outcome in acute alcoholic hepatitis. Lancet 1994, 343:820-823.
382. Simek J, Chmelar V, Melka J, et al. Influence of protracted infusion of glucose and insulin on the composition and regeneration activity of liver after partial hepatectomy in rats. Nature 1967, 213:910-911.
383. Farivar M, Wands JR, Isselbacher KJ, Bucher NL Effect of insulin and glucagon on fulminant murine hepatitis. N Engl J Med 1976, 295:1517-1519.
384. Feher J, Cornides A, Romany A, et al. A prospective multicenter study of insulin and glucagon infusion therapy in acute alcoholic hepatitis. J Hepatol 1987, 5:224-231.
385. Trinchet JC, Balkau B, Poupon RE, et al. Treatment of severe alcoholic hepatitis by infusion of insulin and glucagon: a multicenter sequential trial. Hepatology 1992, 15:76-81.
386. Bird G, Lau JY, Koskinas J, et al. Insulin and glucagon infusion in acute alcoholic hepatitis: a prospective randomized controlled trial. Hepatology 1991, 14:1097-1101.
387. Rambaldi A, Iaquinto G, Gluud C. Anabolic-androgenic steroids for alcoholic liver disease: a Cochrane review. Am J Gastroenterol 2002, 97:1674-1681.
388. Israel Y, Kalant H, Orrego H, et al. Experimental alcohol-induced hepatic necrosis: suppression by propylthiouracil. Proc Natl Acad Sci USA 1975, 72:1137-1141.
389. Orrego H, Kalant H, Israel Y, et al. Effect of short-term therapy with propylthiouracil in patients with alcoholic liver disease. Gastroenterology 1979, 76:105-115.
390. Halle P, Pare P, Kaptein E, et al. Double-blind, controlled trial of propylthiouracil in patients with severe acute alcoholic hepatitis. Gastroenterology 1982, 82:925-931.
391. Iimuro Y, Gallucci RM, Luster MI, et al. Antibodies to tumor necrosis factor alfa attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat. Hepatology 1997, 26:1530-1537.
392. Jalan R, Williams R, Kaser R, et al. Clinical and cytokine response to anti-TNF antibody therapy in severe alcoholic hepatitis. Hepatology 2001, 34:441A.
393. Spahr L, Rubbia-Brandt L, Frossard JL, et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. J Hepatol 2002, 37:448-455.
394. Menon KV, Stadheim L, Kamath PS, et al. A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am J Gastroenterol 2004, 99:255-260.
395. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001, 345:1098-1104.
396. Akerman P, Cote P, Yang SQ, et al. Antibodies to tumor necrosis factor-alpha inhibit liver regeneration after partial hepatectomy. Am J Physiol 1992, 263:G579-G585.
397. Naveau S, Chollet-Martin S, Dharancy S, et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis [see comment]. Hepatology 2004, 39:1390-1397.
398. Jalan R, Sen S, Steiner C, et al. Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis [see comment]. J Hepatol 2003, 38:24-31.
399. Sen S, Mookerjee RP, Cheshire LM, et al. Albumin dialysis reduces portal pressure acutely in patients with severe alcoholic hepatitis. J Hepatol 2005, 43:42-48.
400. Ortega R, Gines P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a
401. Uriz J, Gines P, Cardenas A, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000, 33:43-48.
402. Guevara M, Gines P, Fernandez-Esparrach G, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998, 27:35-41.
403. Orrego H, Blake JE, Blendis LM, et al. Long-term treatment of alcoholic liver disease with propylthiouracil. N Engl J Med 1987, 317:1421-1427.
404. Ehrlich HP, Ross R, Bornstein P Effects of antimicrotubular agents on the secretion of collagen. A biochemical and morphological study. J Cell Biol 1974, 62:390-405.
405. Diegelmann RF, Peterkofsky B Inhibition of collagen secretion from bone and cultured fibroblasts by microtubular disruptive drugs. Proc Natl Acad Sci USA 1972, 69:892-896.
406. Kershenobich D, Uribe M, Suarez GI, et al. Treatment of cirrhosis with colchicine. A double-blind randomized trial. Gastroenterology 1979, 77:532-536.
407. Akriviadis EA, Steindel H, Pinto PC, et al. Failure of colchicine to improve short-term survival in patients with alcoholic hepatitis. Gastroenterology 1990, 99:811-818.
408. Trinchet JC, Beaugrand M, Callard P, et al. Treatment of alcoholic hepatitis with colchicine. Results of a randomized double blind trial. Gastroenterol Clin Biol 1989, 13:551-555.
409. Cortez-Pinto H, Alexandrino P, Camilo ME, et al. Lack of effect of colchicine in alcoholic cirrhosis: final results of a double blind randomized trial. Eur J Gastroenterol Hepatol 2002, 14:377-381.
410. Rambaldi A, Gluud C. Colchicine for alcoholic and nonalcoholic liver fibrosis and cirrhosis. Cochrane Database of Systematic Reviews 2001, 3:002148.
411. Morgan TR, Weiss DG, Nemchausky B, et al. Colchicine treatment of alcoholic cirrhosis: a randomized, placebo-controlled clinical trial of patient survival. Gastroenterology 2005, 128:882-890.
412. Carini R, Comoglio A, Albano E, Poli G. Lipid peroxidation and irreversible damage in the rat hepatocyte model. Protection by the silybin-phospholipid complex IdB 1016. Biochem Pharmacol 1992, 43:2111-2115.
413. Pietrangelo A, Borella F, Casalgrandi G, et al. Antioxidant activity of silybin in vivo during long-term iron overload in rats. Gastroenterology 1995, 109:1941-1949.
414. Masini A, Ceccarelli D, Giovannini F, et al. Iron-induced oxidant stress leads to irreversible mitochondrial dysfunctions and fibrosis in the liver of chronic iron-dosed gerbils. The effect of silybin. J Bioenergetics Biomembranes 2000, 32:175-182.
415. Ferenci P, Dragosics B, Dittrich H, et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol 1989, 9:105-113.
416. Pares A, Planas R, Torres M, et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. J Hepatol 1998, 28:615-621.
417. Mato JM, Camara J, Fernandez de Paz J, et al. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 1999, 30:1081-1089.
418. Lieber CS, Robins SJ, Li J, et al. Phosphatidylcholine protects against fibrosis and cirrhosis in the baboon. Gastroenterology 1994, 106:152-159.
419. Li J, Kim CI, Leo MA, et al. Polyunsaturated lecithin prevents acetaldehyde-mediated hepatic collagen accumulation by stimulating collagenase activity in cultured lipocytes. Hepatology 1992, 15:373-381.
420. Lieber CS Alcoholic liver disease: new insights in pathogenesis lead to new treatments. J Hepatol 2000, 32(suppl):113-128.
421. Lieber CS, Weiss DG, Groszmann R, et al. II. Veterans Affairs cooperative study of polyenylphosphatidylcholine in alcoholic liver disease. Alcoholism Clin Exp Res 2003, 27:1765-1772.
422. Starzl TE, Van Thiel D, Tzakis AG, et al. Orthotopic liver transplantation for alcoholic cirrhosis. JAMA 1988, 260:2542-2544.
423. European Liver Transplant Registry. 2001. http://www.ELTR.org.
424. Belle SH, Beringer KC, Detre KM Liver transplantation for alcoholic liver disease in the United States: 1988 to 1995. Liver Transplant Surg 1997, 3:212-219.
425. Neuberger J, Schulz KH, Day C, et al. Transplantation for alcoholic liver disease. J Hepatol 2002, 36:130-137.
426. Wiesner RH, Lombardero M, Lake JR, et al. Liver transplantation for end-stage alcoholic liver disease: an assessment of outcomes. Liver Transplant Surg 1997, 3:231-239.
427. Bird GL, O'Grady JG, Harvey FA, et al. Liver transplantation in patients with alcoholic cirrhosis: selection criteria and rates of survival and relapse. Br Med J 1990, 301:15-17.
428. Burra P, De Bona M, Canova D, et al. Longitudinal prospective study on quality of life and psychological distress before and one year after liver transplantation. Acta Gastroenterol Belg 2005, 68:19-25.
429. Propst A, Propst T, Zangerl G, et al. Prognosis and life expectancy in chronic liver disease. Digest Dis Sci 1995, 40:1805-1815.
430. Poynard T, Barthelemy P, Fratte S, et al. Evaluation of efficacy of liver transplantation in alcoholic cirrhosis by a case-control study and simulated controls. Lancet 1994, 344:502-507.
431. Lucey MR, Carr K, Beresford TP, et al. Alcohol use after liver transplantation in alcoholics: a clinical cohort follow-up study. Hepatology 1997, 25:1223-1227.
432. Gerhardt TC, Goldstein RM, Urschel HC, et al. Alcohol use following liver transplantation for alcoholic cirrhosis. Transplant Proc 1996, 62:1060-1063.
433. Berlakovich GA, Steininger R, Herst M, et al. Efficacy of liver transplantation for alcoholic cirrhosis with respect to recidivism and compliance. Transplant Proc 1994, 58:560-565.
434. Kumar S, Stauber RE, Gavaler JS, et al. Orthotopic liver transplantation for alcoholic liver disease. Hepatology 1990, 11:159-164.
435. Osorio RW, Ascher NL, Avery M, et al. Predicting recidivism after orthotopic liver transplantation for alcoholic liver disease. Hepatology 1994, 20:105-110.
436. Pageaux GP, Michel J, Coste V, et al. Alcoholic cirrhosis is a good indication for liver transplantation, even for cases of recidivism [see comment]. Gut 1999, 45:421-426.
437. Foster PF, Fabrega F, Karademir S, et al. Prediction of abstinence from ethanol in alcoholic recipients following liver transplantation. Hepatology 1997, 25:1469-1477.
438. Anand AC, Ferraz-Neto BH, Nightingale P, et al. Liver transplantation for alcoholic liver disease: evaluation of a selection protocol. Hepatology 1997, 25:1478-1484.
439. Burra P, Mioni D, Cecchetto A, et al. Histological features after liver transplantation in alcoholic cirrhotics. J Hepatol 2001, 34:716-722.
440. Cuadrado A, Fabrega E, Casafront F, Pons-Romero F Alcohol recidivism impairs long-term patient survival after orthotopic liver transplantation for alcoholic liver disease. Liver Transplant 2005, 11:420-426.
441. Neuberger J, Adams D, MacMaster P, et al. Assessing priorities for allocation of donor liver grafts: survey of public and clinicians. Br Med J 1998, 317:172-175.
442. Miguet M, Monnet E, Vanlemmens C, et al. Predictive factors of alcohol relapse after orthotopic liver transplantation for alcoholic liver disease. Gastroenterol Clin Biol 2004, 28:845-851.
443. Veldt BJ, Laine F, Guillygomar'h A, et al. Indication of liver transplantation in severe alcoholic liver cirrhosis: quantitative evaluation and optimal timing. J Hepatol 2002, 36:93-98.
444. Lucey MR Is liver transplantation an appropriate treatment for acute alcoholic hepatitis?. J Hepatol 2002, 36:829-831.
445. Shakil AO, Pinna A, Demetris J, et al. Survival and quality of life after liver transplantation for acute alcoholic hepatitis. Liver Transplant Surg 1997, 3:240-244.
446. Tome S, Martinez-Rey C, Gonzalez-Quintela A, et al. Influence of superimposed alcoholic hepatitis on the outcome of liver transplantation for end-stage alcoholic liver disease [see comment]. J Hepatol 2002, 36:793-798.